Archives for: June 8th, 2022

CorMedix to Participate at the JMP Securities Life Sciences Conference

Written by Sam Nelson on June 8, 2022

Berkeley Heights, NJ – June 8, 2022 – CorMedix Inc. (Nasdaq:…

CorMedix Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

Written by Sam Nelson on May 12, 2022

Conference Call Scheduled for Today at 4:30 p.m. Eastern Time…

CORMEDIX INC. ANNOUNCES LEADERSHIP UPDATES AND OPERATIONAL CHANGES

Written by Sam Nelson on May 12, 2022

Berkeley Heights, NJ – May 12, 2022 – CorMedix Inc. (Nasdaq: CRMD),…

CORMEDIX INC. TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MAY 12

Written by Sam Nelson on May 3, 2022

Berkeley Heights, NJ – May 3, 2022 – CorMedix Inc. (Nasdaq: CRMD),…

CORMEDIX INC. ANNOUNCES SCIENTIFIC ADVISORY BOARD TO SUPPORT COMMERCIALIZATION and pipeline development

Written by Sam Nelson on April 7, 2022

Berkeley Heights, NJ – April 7, 2022 – CorMedix Inc. (Nasdaq:…

CORMEDIX INC. to Present at the 21st Annual Needham Virtual Healthcare Conference

Written by Sam Nelson on April 4, 2022

Berkeley Heights, NJ – April 4, 2022 – CorMedix Inc. (Nasdaq:…

CORMEDIX INC. REPORTS fourth QUARTER and full year 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Written by Sam Nelson on March 29, 2022

Conference Call Scheduled for Today at 4:30 p.m. Eastern Time…

CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE of RESUBMISSION of NEW DRUG APPLICATION FOR DEFENCATH

Written by Sam Nelson on March 28, 2022

Berkeley Heights, NJ – March 28, 2022 – CorMedix Inc. (Nasdaq:…

CorMedix Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update on March 29

Written by Sam Nelson on March 22, 2022

Berkeley Heights, NJ – March 22, 2022 – CorMedix Inc. (Nasdaq: CRMD),…

CORMEDIX INC. ANNOUNCES THE APPOINTMENT OF CHIEF EXECUTIVE OFFICER

Written by Sam Nelson on March 17, 2022

Joseph Todisco to join CorMedix as Chief Executive Officer; Brings…

CORMEDIX INC. ANNOUNCES RESUBMISSION of NEW DRUG APPLICATION FOR DEFENCATH

Written by Sam Nelson on February 28, 2022

Berkeley Heights, NJ – February 28, 2022 – CorMedix Inc. (Nasdaq:…

CORMEDIX TO PARTICIPATE IN UPCOMING JANUARY CONFERENCES

Written by Sam Nelson on January 4, 2022

Berkeley Heights, NJ – January 4, 2022 – CorMedix Inc. (Nasdaq: CRMD),…

CORMEDIX INC. REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Written by Sam Nelson on November 9, 2021

Conference Call Scheduled for Today at 4:30 p.m. Eastern Time…

CorMedix Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9

Written by Sam Nelson on November 2, 2021

Berkeley Heights, NJ – November 2, 2021 – CorMedix Inc. (Nasdaq:…

CORMEDIX INC. ANNOUNCES ABSTRACTS AT UPCOMING CONFERENCES SHOWING PATIENT OUTCOMES AND ECONOMIC BURDEN OF CRBSI

Written by Sam Nelson on October 20, 2021

Berkeley Heights, NJ – October 20, 2021 – CorMedix Inc. (Nasdaq:…

CORMEDIX INC. ANNOUNCES EXECUTIVE LEADERSHIP CHANGES

Written by Sam Nelson on October 4, 2021

Berkeley Heights, NJ – October 4, 2021 – CorMedix Inc. (Nasdaq:…

CORMEDIX INC. ANNOUNCES REGULATORY UPDATE

Written by Sam Nelson on September 7, 2021

Berkeley Heights, NJ – September 7, 2021 – CorMedix Inc. (Nasdaq:…

CORMEDIX INC. REPORTS SECOND QUARTER AND SIX MONTH 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Written by Sam Nelson on August 12, 2021

Conference Call Scheduled for Today at 4:30 p.m. Eastern Time…

CorMedix Inc. to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on August 12

Written by Sam Nelson on July 28, 2021

Berkeley Heights, NJ – July 28, 2021 – CorMedix Inc. (Nasdaq:…

CorMedix Inc. Completes Sale of $1.3 Million of NOL Tax Benefits Through The New Jersey Economic Development Authority Program

Written by Sam Nelson on June 10, 2021

Berkeley Heights, NJ – June 10, 2021 – CorMedix Inc. (Nasdaq:…